Market Cap (In USD)
152.91 Million
Revenue (In USD)
-
Net Income (In USD)
-117.5 Million
Avg. Volume
1.44 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.13-16.24
- PE
- -1.35
- EPS
- -1.6
- Beta Value
- 0.871
- ISIN
- US65487U1088
- CUSIP
- 65487U108
- CIK
- 1787400
- Shares
- 70957600.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Paul J. Hastings
- Employee Count
- -
- Website
- https://www.nkartatx.com
- Ipo Date
- 2020-07-10
- Details
- Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
More Stocks
-
CS
-
9547
-
0QJQZEAL Network SE
0QJQ
-
PRTEsprinet S.p.A.
PRT
-
HUDI
-
002698
-
300555
-
LDOLeonardo S.p.a.
LDO